Midodrine Effect on the Mortality Rates in Septic Shock Patients

Last updated: February 27, 2025
Sponsor: Noha Mansour
Overall Status: Completed

Phase

2

Condition

Sepsis And Septicemia

Low Blood Pressure (Hypotension)

Treatment

Midodrine Oral Tablet

Clinical Study ID

NCT05778838
2022-211
  • Ages > 18
  • All Genders

Study Summary

Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult aged 18 years or older diagnosed with septic shock.

  • Hypotensive and require IV vasopressor for more than 24 hours.

Exclusion

Exclusion Criteria:

  • Hypovolemic shock.

  • Severe organic heart disease (ejection fraction <30 percent).

  • Bradycardia (HR<50 b/m).

  • Chronic kidney disease (serum creatinine >2mg/dl).

  • Thyrotoxicosis.

  • Pheochromocytoma.

  • Known allergy to midodrine.

  • Unable to administer an oral medication.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Midodrine Oral Tablet
Phase: 2
Study Start date:
November 07, 2022
Estimated Completion Date:
January 24, 2024

Connect with a study center

  • Mansoura University

    Mansoura, 35516
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.